Your browser doesn't support javascript.
loading
Bortezomib Induced Tumor Lysis Syndrome in Multiple Myeloma
Soonchunhyang Medical Science ; : 31-33, 2013.
Article in English | WPRIM | ID: wpr-8456
ABSTRACT
The tumor lysis syndrome (TLS) commonly occurs in the lymphoproliferative disorder, either spontaneously or in response to therapy. TLS is uncommon in multiple myeloma. However, with the use of bortezomib in the treatment of multiple myeloma, cases of TLS have been reported. We report here threepatients who presented with TLS after the administration of bortezomib. Two of them presented mild symptoms and recovered with hydration only. However, death of the other patient was associated with TLS. We should monitor patients who had high tumor burden, especially in early phase of bortezomib therapy and appropriate prophylaxis for high risk patient is also needed.
Subject(s)

Full text: Available Index: WPRIM (Western Pacific) Main subject: Organothiophosphorus Compounds / Pyrazines / Boronic Acids / Tumor Lysis Syndrome / Tumor Burden / Bortezomib / Lymphoproliferative Disorders / Multiple Myeloma Limits: Humans Language: English Journal: Soonchunhyang Medical Science Year: 2013 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Organothiophosphorus Compounds / Pyrazines / Boronic Acids / Tumor Lysis Syndrome / Tumor Burden / Bortezomib / Lymphoproliferative Disorders / Multiple Myeloma Limits: Humans Language: English Journal: Soonchunhyang Medical Science Year: 2013 Type: Article